Navigation Links
AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
Date:10/8/2009

TUSTIN, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company through its wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI) announced today it has entered into an exclusive 5-year marketing and distribution agreement with Grifols USA, LLC. Under the terms of the agreement, Grifols USA, LLC will market and sell ADI's DR-70 Onko-Sure cancer test for the monitoring of colorectal cancer (CRC) to hospitals, clinical labs, clinics, and other healthcare organizations throughout the US.

Grifols is a publicly-traded, multinational healthcare products manufacturer and distributor. The company has business operations in more than 90 countries worldwide focused on the research and development, manufacturing, distribution, marketing, sales, and customer support for a diverse range of in-house and 3rd party healthcare products and services, now including ADI's DR-70 Onko-Sure cancer test.

The agreement is the latest milestone ADI has achieved in support of the company's aggressive commercialization strategy for Onko-Sure. According to the agreed upon terms, Grifols USA, LLC has the rights to market and distribute ADI's Onko-Sure cancer test specifically for the monitoring of colorectal cancer in the US. This includes developing and implementing a marketing strategy to drive product awareness; educate clinical laboratories and physicians; and generate product sales.

According to Patricia Silver, General Manager, US Diagnostic Division at Grifols USA, LLC, "We are intensely dedicated to providing hospitals, labs and clinics with highly innovative and in-demand products and services which improve the level and quality of patient health care around the world, and we are very pleased to support the commercialization of ADI's Onko-Sure cancer test in the US. ADI has developed a new option to assist physicians and their patients in monitoring the recurrence of cancer and we are excited to bring it to the marketplace."

"We are extremely pleased to announce a top-tier distribution partnership for our Onko-Sure cancer test in the USA," commented Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals & ADI. "We are making great progress on our commercialization plan for Onko-Sure(TM), and with this latest agreement, doing so with one of the most recognized, respected and experienced companies in the healthcare sector. We are dedicated to establishing a strong, long-lasting and highly successful relationship with the Grifols team - one that will help make Onko-Sure(TM) the standard in cancer testing and deliver direct value to our customers, patients, and shareholders."

With the exception of heart disease, cancer causes more deaths than any other medical condition in the world. According to the World Health Organization (WHO), cancer is rapidly becoming the leading cause of death worldwide and is expected to overtake heart disease by 2010. Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer deaths irrespective of gender in the US, and one of the most commonly diagnosed of all cancers. Last year, there were approximately 151,000 new cases diagnosed in the US, roughly 51,000 deaths due to the disease*, and almost half of all patients thought to be "cured" are expected to develop a recurrence of CRC within 5 years - usually due to undetected metastases.** Frequent surveillance of diagnosed patients is recommended.

In the USA Onko-Sure has been cleared for the monitoring of colorectal cancer by the US FDA (July 2008). ADI continues to expand its commercialization of Onko-Sure(TM) in select international markets. For additional information on ADI and its portfolio of products visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at kszarkowitz@Radient-Pharma.com or 1.206.310.5323.

*National Cancer Institute: Cancer Facts and Figures 2009.

**Bull World Health Organ: Shike M, Winawer SJ, Greenwald PH, et al.

About Radient Pharma:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and premium skin care products.

About Grifols S.A.

Grifols S.A. is a Spain-based company engaged in the healthcare sector and is listed on Ibex-35 stock market. Grifols is involved in the research, development, manufacturing and marketing of plasma derivates, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Founded in 1940, Grifols currently operates in 90 countries with more than 6.000 employees, 26 subsidiaries with combined gross revenues over Euro 800 million.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    Radient Pharmaceuticals Corporation Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@radient-pharma.com
    (Tel:) 206.310.5323

SOURCE Radient Pharmaceuticals Corporation


'/>"/>
SOURCE Radient Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting
2. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
3. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
4. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
5. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
6. Clinical Logistics Enters Partnership with Gentris Corporation
7. Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
8. Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
9. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
10. Top Medical Research Centers Form Velos Advisory Group for Service-Oriented Architecture
11. Jubilant Enters Research Collaboration With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):